Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?

Lupus

Volumn 25, Issue 10, 2016, Pages 1097-1101

  Kalunian, K C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biologics; interferon; interferon signature; plasmacytoid dentritic cells

Indexed keywords

ANIFROLUMAB; CORTICOSTEROID; INTERFERON; INTERFERON RECEPTOR; RONTALIZUMAB; SIFALIMUMAB; ALPHA INTERFERON; MONOCLONAL ANTIBODY;

ARTICLE; B LYMPHOCYTE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RECEPTOR BINDING; HERPES ZOSTER; HUMAN; INFLUENZA; INTERFERON PRODUCTION; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE II AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84982899698     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203316652495     Document Type: Article

References (27)

1. Tsokos GC,. Systemic lupus erythematosus. N Eng J Med 2011; 365: 2110-2121.
2. Elkon KB, Stone W,. Type I interferon and systemic lupus erythematosus. J Interferon Cytokine Res 2011; 31: 803-812.
3. Ronnblom L,. The type I interferon system in the etiopathogeneis of autoimmune diseases. Ups J Med Sci 2011; 116: 227-2237.
4. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J,. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2991; 294: 1540-1543.
5. Guiducci C, Gong M, Xu Z, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010; 465: 937-941.
6. Fitzgerald-Bocarsly P, Dai J, Singh S,. Plasmacytoid dendritic cells and type I IFN: 50 years of concergent history. Cytokine Growth Factor Rev 2008; 19: 3-19.
7. Niewold TB, Hua J, Lehman TJ, et al. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007; 8: 492-502.
8. Hahn BH,. Antibodies to DNA. N Eng J Med 1998; 338: 1359-1368.
9. Banchereau J, Pascual V,. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006; 25: 383-392.
10. Ytterberg SR, Schnitzer TJ,. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982; 25: 401-406.
11. Hooks JJ, Moutsopoulos HM, Geis AS, et al. Immune interferon in the circulation of patients with auto-immune disease. N Eng J Med 1979; 301: 5-8.
12. Postal M,. Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus. Clinics 2012; 62: 157-162.
13. Weckerle CE, Franek BS, Kelly JA, et al. Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum 2011; 63: 1044-1053.
14. Dall'era MC, Cardarelli PM, Preston BT, et al. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005; 64: 492-502.
15. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610-2615.
16. Crow MK,. Type I interferon and autoimmune disease. Autoimmunity 2003; 36: 445-446.
17. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signature in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-723.
18. Moser KL, Kelly JA, Lessard CJ, et al. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009; 10: 373-379.
19. Lee HS, Bae SC,. What can we learn from genetic studies of systemic lupus erytjeamtosus? Implications of genetic heterogeneity among populations in SLE. Lupus 2010; 19: 1452-1459.
20. Sestak AL, Fomrohr BG, Harley JB, et al. The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann Rheum Dis 2011; 70 (Suppl. 1): i37-i43.
21. Niewold TB, Swedler WI,. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005; 24: 178-181.
22. Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R,. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011; 186: 4794-4804.
23. An J, Woodward JJ, Sasaki T, Minie M, Elkon KB,. Cutting edge: antimalarial drugs inhibit INF-β through blockade of cyclic GMP-AMP synthase-DNA interaction. J Immunol 2015; 194: 4089-4093.
24. Kalunian KC, Merrill JT, Maciuca R, et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis 2016; 75: 196-202.
25. Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study. Ann Rheum Dis. Epub ahead of print 23 March 2016. DOI: 10.1136/annrheumdis-2015-208562.
26. Furie R, Merrill J, Werth V, et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus (SLE) [abstract]. Arthritis Rheumatol 2015; 67 (suppl. 10), http://acrabstracts.org/abstract/anifrolumab-an-anti-interferon-alpha-receptor-monoclonal-antibody-in-moderate-to-severe-systemic-lupus-erythematosus-sle/ (2015, accessed 14 April 2016).
27. Peng L, Oganesyan V, Wu H, Dall'Acqua WF, Damschroder MM. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-a receptor 1 antibody.MAbs. 2015; 7: 428-439.